| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (NCT04585958) | National Cancer Institute (NCI) | 2021-05-21 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (NCT04387071) | University of Southern California | 2021-04-29 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor (NCT04800627) | M.D. Anderson Cancer Center | 2021-03-29 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (NCT04729725) | M.D. Anderson Cancer Center | 2021-02-09 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628) | National Cancer Institute (NCI) | 2020-09-01 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (NCT04317105) | National Cancer Institute (NCI) | 2020-07-17 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713) | National Cancer Institute (NCI) | 2020-06-30 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194) | National Cancer Institute (NCI) | 2020-04-07 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912) | M.D. Anderson Cancer Center | 2020-03-17 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCT03842228) | National Cancer Institute (NCI) | 2019-11-21 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| SBRT-based PArtial Tumor Irradiation of HYpoxic Segment (NCT04168320) | Klinikum Klagenfurt am Wörthersee | 2018-10-30 |
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (NCT03030378) | National Cancer Institute (NCI) | 2018-05-30 |
| Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer (NCT02862275) | National Cancer Institute (NCI) | 2017-05-24 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931) | National Cancer Institute (NCI) | 2016-07-22 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer (NCT02317874) | National Cancer Institute (NCI) | 2015-09-08 |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740) | National Cancer Institute (NCI) | 2014-03-26 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (NCT01364051) | National Cancer Institute (NCI) | 2011-05-25 |